Cardiff Oncology Stock News

Cardiff Oncology Inc. (NASDAQ:CRDF) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 6.51% to the previous days close as strong demand from buyers drove the stock to $5.73. Actively observing the price movement in the last trading, the stock closed the session at $5.38, falling within a range of $5.21 Is Cardiff Oncology Inc. (NASDAQ: CRDF) A Stock A New Investor Should Consider Now? Read More »

Maxim Group reissued their buy rating on shares of Cardiff Oncology (NASDAQ:CRDF) in a report published on Friday, Analyst Price Targets reports. The firm currently has a $24.00 target price on the stock. Other equities analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a buy rating and set a $26.00 []

Cardiff Oncology is a prime takeover target heading into 2022.

Cardiff Oncology Inc. (NASDAQ:CRDF) price on Friday, November 19, fall -7.73% below its previous days close as a downside momentum from buyers pushed the stocks value to $5.73. A look at the stocks price movement, the level at last check in todays session was $6.21, moving within a range at $5.60 and $6.29. The beta Cardiff Oncology Inc. (CRDF) Is A Possible Investment At Current Levels Read More »

Cardiff Oncology (NASDAQ:CRDF) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability. Institutional & Insider Ownership 67.0% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 28.5% []

Cardiff Oncology Inc. (NASDAQ:CRDF)s traded shares stood at 13.17 million during the latest session, with the companys beta value hitting 1.64. At the last check today, the stocks price was $5.98, to imply an increase of 14.43% or $0.75 in intraday trading. The CRDF shares 52-week high remains $25.50, putting it -326.42% down since that Cardiff Oncology Inc. (NASDAQ: CRDF) Now Carries A 12-Month Price Target Of $26.00. Read More »

Pfizer Inc (NYSE: PFE ) has made a $15 million equity investment in Cardiff Oncology Inc (NASDAQ: CRDF ) as part of the Pfizer Breakthrough Growth Initiative. Pfizer purchased 2.4 million shares of Cardiff Oncology''s shares at $6.22 Full story available on Benzinga.com

The clinical-stage oncology specialist is getting an infusion of cash from pharmaceutical giant Pfizer.

(RTTNews) - Pfizer Inc. (PFE) has made a $15 million equity investment in Cardiff Oncology Inc. (CRDF), as part of the Pfizer Breakthrough Growth Initiative, Cardiff said in a statement on Thursday. Pfizer Breakthrough Growth Initiativ is a program focused on funding innovative science to meet patient needs. In Thursday pre-market trade, CRDF

Pfizer Inc (NYSE: PFE) has made a $15 million equity investment in Cardiff Oncology Inc (NASDAQ: CRDF) as part of the Pfizer Breakthrough Growth Initiative. Pfizer purchased 2.4 million shares of

The stock price of Cardiff Oncology Inc (NASDAQ: CRDF) increased by over 19% pre-market today. This is why it happened.

Brokerages predict that Cardiff Oncology, Inc. (NASDAQ:CRDF) will report ($0.17) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Cardiff Oncologys earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.20). Cardiff Oncology reported earnings per share of ($0.19) during the same quarter last year, []

Geode Capital Management LLC boosted its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 147.0% during the second quarter, HoldingsChannel.com reports. The fund owned 514,981 shares of the companys stock after purchasing an additional 306,526 shares during the period. Geode Capital Management LLCs holdings in Cardiff Oncology were worth $3,424,000 at the end of the most []

Vanguard Group Inc. lifted its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,646,044 shares of the companys stock after buying an additional 72,134 shares during the period. Vanguard Group Inc. owned approximately []